Bristol-Myers Squibb Company (BMY)

Operating profit margin

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating income	US$ in thousands	-12,554,000	-9,290,000	-10,290,000	-17,133,000	-1,416,000
Revenue	US$ in thousands	48,300,000	45,006,000	46,159,000	46,385,000	42,518,000
Operating profit margin		-25.99%	-20.64%	-22.29%	-36.94%	-3.33%

December 31, 2024 calculation

Operating profit margin = Operating income ÷ Revenue
= $-12,554,000K ÷ $48,300,000K
= -25.99%

The operating profit margin of Bristol-Myers Squibb Company has shown a declining trend over the years based on the provided data. In December 2020, the company had an operating profit margin of -3.33%, indicating that the company was not efficiently converting its revenue into profit. This negative trend worsened significantly in December 2021, with the operating profit margin plummeting to -36.94%, which could suggest poor cost management or declining revenue.

There was a slight improvement in December 2022, as the operating profit margin increased to -22.29%, although it still remained negative. However, in December 2023 and December 2024, the operating profit margin decreased again to -20.64% and -25.99%, respectively, indicating the company continued to face challenges in generating profits from its operations.

Overall, the negative operating profit margins suggest that Bristol-Myers Squibb Company may have faced difficulties in controlling operating expenses or experienced declining revenue relative to its costs during the analyzed period. Further analysis of the company's financial performance and strategic decisions may be warranted to understand the factors contributing to this downward trend in operating profit margin.